A significant milestone has been reached for the biotechnology firm Think Biosciences with its recent Series A funding round, which raised $55 million (approximately 202 million AED). This strategic investment paves the way for accelerating clinical development and expanding the company’s synthetic biology platform. The funding round surpassed its initial target and was led by prominent global investors, including participation from الهلال للمشاريع الناشئة, reflecting an increasing confidence in the company’s potential to make groundbreaking advancements in drug discovery.
The funds will be allocated to expedite the development of Think Bio’s innovative small molecule programs and to enhance its scientific platform capabilities that enable the identification of new binding pockets on proteins that have historically eluded drug development efforts. This advance signifies a transformative step in the pharmaceutical industry, opening avenues for treatments aimed at complex genetic diseases that currently lack effective therapeutic solutions.
The significance of this funding round is particularly pronounced as it supports the company’s main program, which focuses on genetic mutations related to Noonan syndrome, a rare hereditary condition that does not have therapies targeting its biological causes. With this financial boost, Think Biosciences is positioned to accelerate its transition from discovery to advanced development stages, increasing the likelihood of delivering the first targeted small molecular treatment for these conditions.
Moreover, this funding round is a crucial step in reinforcing the company’s position among the next generation of research-driven biotech firms capable of competing on a global scale. In addition to capital infusion, the partnerships with strategic investors provide essential scientific, operational expertise, and global networks, facilitating the establishment of a company capable of expanding its scientific and commercial impact.
Thus, the importance of this funding round goes beyond supporting the financial growth of Think Biosciences; it marks a transformative moment that enhances its ability to redefine the boundaries of drug discovery and expedite the development of innovative treatments for long-standing unmet medical needs.
Tushar Singhvi, Executive Vice President and Head of Investments at الهلال للمشاريع, stated, “Think Biosciences is developing a distinctive platform that integrates synthetic biology with drug discovery, broadening the therapeutic horizons and providing new solutions for patients facing significant unmet medical needs. This investment reflects our high confidence in the Think Bio approach and the opportunity to build a leading biotech company that can create a tangible impact for patients worldwide.”
Dr. Jerome Fox, co-founder and CEO of Think Biosciences, remarked, “Our primary program has the potential to make a real difference in the lives of many patients with Noonan syndrome, offering them a chance to live more normal lives. We appreciate the support of our investors in our vision to develop transformative therapies for patients who are in dire need.”
Dr. Damir Ilic, Head of Life Sciences at الهلال للمشاريع الناشئة, who will join the company’s board as an observer, added, “Think Biosciences is addressing one of the major hurdles in drug discovery by enabling the development of small molecules targeting historically considered undruggable targets. The Noonan syndrome program showcases the immense potential of this platform in areas that currently lack approved treatments.”